

# Ron van Schaik

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8073733/publications.pdf>

Version: 2024-02-01

59  
papers

3,774  
citations

159585

30  
h-index

138484

58  
g-index

62  
all docs

62  
docs citations

62  
times ranked

4965  
citing authors

#	ARTICLE	IF	CITATIONS
1	Treatment-driven tumour heterogeneity and drug resistance: Lessons from solid tumours. <i>Cancer Treatment Reviews</i> , 2022, 104, 102340.	7.7	21
2	Genetic polymorphism in <i>AT1C</i> is associated with effectiveness and toxicity of pemetrexed in non-small-cell lung cancer. <i>Thorax</i> , 2021, 76, 1150-1153.	5.6	4
3	Policy and Practice Review: A First Guideline on the Use of Pharmacogenetics in Clinical Psychiatric Practice. <i>Frontiers in Pharmacology</i> , 2021, 12, 640032.	3.5	14
4	Recommendations for Clinical CYP2D6 Genotyping Allele Selection. <i>Journal of Molecular Diagnostics</i> , 2021, 23, 1047-1064.	2.8	73
5	What do we need to obtain high quality circulating tumor DNA (ctDNA) for routine diagnostic test in oncology? " Considerations on pre-analytical aspects by the IFCC workgroup cfDNA. <i>Clinica Chimica Acta</i> , 2021, 520, 168-171.	1.1	20
6	High levels of several antipsychotics and antidepressants due to a pharmacogenetic cause: a case report. <i>Pharmacogenomics</i> , 2019, 20, 567-570.	1.3	3
7	Androgen receptor (AR) splice variant 7 and full-length AR expression is associated with clinical outcome: a translational study in patients with castrate-resistant prostate cancer. <i>BJU International</i> , 2019, 124, 693-700.	2.5	32
8	Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report. <i>Therapeutic Drug Monitoring</i> , 2019, 41, 261-307.	2.0	374
9	A population pharmacokinetic model to predict the individual starting dose of tacrolimus in adult renal transplant recipients. <i>British Journal of Clinical Pharmacology</i> , 2019, 85, 601-615.	2.4	56
10	User considerations in assessing pharmacogenomic tests and their clinical support tools. <i>Npj Genomic Medicine</i> , 2018, 3, 26.	3.8	38
11	Cytochrome P450 genotype and aggressive behavior on selective serotonin reuptake inhibitors. <i>Pharmacogenomics</i> , 2018, 19, 1097-1099.	1.3	0
12	Personalized laboratory medicine: a patient-centered future approach. <i>Clinical Chemistry and Laboratory Medicine</i> , 2018, 56, 1981-1991.	2.3	33
13	<i>CYP450</i> genotype and aggressive behavior on selective serotonin reuptake inhibitors. <i>Pharmacogenomics</i> , 2017, 18, 613-620.	1.3	5
14	The combination of CYP3A4*22 and CYP3A5*3 single-nucleotide polymorphisms determines tacrolimus dose requirement after kidney transplantation. <i>Pharmacogenetics and Genomics</i> , 2017, 27, 313-322.	1.5	52
15	Prevention of fluoropyrimidine toxicity: do we still have to try our patient's luck?. <i>Annals of Oncology</i> , 2017, 28, 183.	1.2	12
16	A Randomized Controlled Trial Comparing the Efficacy of Cyp3a5 Genotype-Based With Body-Weight-Based Tacrolimus Dosing After Living Donor Kidney Transplantation. <i>American Journal of Transplantation</i> , 2016, 16, 2085-2096.	4.7	129
17	Clinical validity of new genetic biomarkers of irinotecan neutropenia: an independent replication study. <i>Pharmacogenomics Journal</i> , 2016, 16, 54-59.	2.0	20
18	Pharmacogenetic aspects of the use of tacrolimus in renal transplantation: recent developments and ethnic considerations. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2016, 12, 555-565.	3.3	106

#	ARTICLE	IF	CITATIONS
19	Role of genetic variation in docetaxel-induced neutropenia and pharmacokinetics. <i>Pharmacogenomics Journal</i> , 2016, 16, 519-524.	2.0	17
20	Increased liver enzyme levels during azathioprine treatment: beware of concomitant use of proton pump inhibitors. <i>British Journal of Dermatology</i> , 2015, 173, 1338-1339.	1.5	3
21	Association of CYP3A variants with kidney transplant outcomes. <i>Renal Failure</i> , 2015, 37, 562-566.	2.1	9
22	Multidrug and toxin extrusion 1 and human organic cation transporter 1 polymorphisms in patients with castration-resistant prostate cancer receiving metformin (SAKK 08/09). <i>Prostate Cancer and Prostatic Diseases</i> , 2015, 18, 167-172.	3.9	12
23	Implementation of a companion diagnostic in the clinical laboratory: The BRAF example in melanoma. <i>Clinica Chimica Acta</i> , 2015, 439, 128-136.	1.1	5
24	Association Analysis of Genetic Polymorphisms in Genes Related to Sunitinib Pharmacokinetics, Specifically Clearance of Sunitinib and SU12662. <i>Clinical Pharmacology and Therapeutics</i> , 2014, 96, 81-89.	4.7	67
25	CYP2C9*2 Allele Increases Risk for Hypoglycemia in POR*1/*1 Type 2 Diabetic Patients Treated with Sulfonylureas. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 2014, 122, 60-63.	1.2	30
26	Cushing's disease and hypertension: in vivo and in vitro study of the role of the renin-angiotensin-aldosterone system and effects of medical therapy. <i>European Journal of Endocrinology</i> , 2014, 170, 181-191.	3.7	19
27	The 5-HT <sub>2C</sub> receptor gene Cys23Ser polymorphism influences the intravaginal ejaculation latency time in Dutch Caucasian men with lifelong premature ejaculation. <i>Asian Journal of Andrology</i> , 2014, 16, 607.	1.6	31
28	CYP2C19*2 predicts substantial tamoxifen benefit in postmenopausal breast cancer patients randomized between adjuvant tamoxifen and no systemic treatment. <i>Breast Cancer Research and Treatment</i> , 2013, 139, 649-655.	2.5	21
29	CYP2D6 genotype in relation to tamoxifen efficacy in a Dutch cohort of the tamoxifen exemestane adjuvant multinational (TEAM) trial. <i>Breast Cancer Research and Treatment</i> , 2013, 140, 363-373.	2.5	43
30	Genetic variation in the ABCC2 gene is associated with dose decreases or switches to other cholesterol-lowering drugs during simvastatin and atorvastatin therapy. <i>Pharmacogenomics Journal</i> , 2013, 13, 251-256.	2.0	35
31	Doubt About the Feasibility of Preemptive Genotyping. <i>Clinical Pharmacology and Therapeutics</i> , 2013, 93, 233-233.	4.7	9
32	5-HIAA excretion is not associated with bone metabolism in carcinoid syndrome patients. <i>Bone</i> , 2012, 50, 1260-1265.	2.9	13
33	Effects of CYP Induction by Rifampicin on Tamoxifen Exposure. <i>Clinical Pharmacology and Therapeutics</i> , 2012, 92, 62-67.	4.7	34
34	Pharmacogenetics: From Bench to Byte— An Update of Guidelines. <i>Clinical Pharmacology and Therapeutics</i> , 2011, 89, 662-673.	4.7	869
35	Polymorphisms in genes involved in vincristine pharmacokinetics or pharmacodynamics are not related to impaired motor performance in children with leukemia. <i>Leukemia Research</i> , 2010, 34, 154-159.	0.8	40
36	The impact of CYP2D6-predicted phenotype on tamoxifen treatment outcome in patients with metastatic breast cancer. <i>British Journal of Cancer</i> , 2010, 103, 765-771.	6.4	56

#	ARTICLE	IF	CITATIONS
37	Genetic Techniques for Pharmacogenetic Analyses. <i>Current Pharmaceutical Design</i> , 2010, 16, 231-237.	1.9	8
38	The CYP2C19*17 genotype is associated with lower imipramine plasma concentrations in a large group of depressed patients. <i>Pharmacogenomics Journal</i> , 2010, 10, 219-225.	2.0	35
39	Considerations for the development of a reference method for sequencing of haploid DNA – an opinion paper on behalf of the IFCC Committee on Molecular Diagnostics. <i>International Federation of Clinical Chemistry and Laboratory Medicine. Clinical Chemistry and Laboratory Medicine</i> , 2009, 47, 1343-50.	2.3	9
40	Genetic Variation in the CYP2D6 Gene Is Associated With a Lower Heart Rate and Blood Pressure in $\beta$ -Blocker Users. <i>Clinical Pharmacology and Therapeutics</i> , 2009, 85, 45-50.	4.7	130
41	Genotypes Associated With Reduced Activity of VKORC1 and CYP2C9 and Their Modification of Acenocoumarol Anticoagulation During the Initial Treatment Period. <i>Clinical Pharmacology and Therapeutics</i> , 2009, 85, 379-386.	4.7	32
42	UGT1A9 -275T>A/-2152C>T Polymorphisms Correlate With Low MPA Exposure and Acute Rejection in MMF/Tacrolimus-Treated Kidney Transplant Patients. <i>Clinical Pharmacology and Therapeutics</i> , 2009, 86, 319-327.	4.7	112
43	Genetic variation in the organic cation transporter 1 is associated with metformin response in patients with diabetes mellitus. <i>Pharmacogenomics Journal</i> , 2009, 9, 242-247.	2.0	198
44	Polymorphisms in the Multidrug Resistance Gene MDR1 (ABCB1) Predict for Molecular Resistance in Patients with Newly Diagnosed Chronic Myeloid Leukemia (CML) Receiving High-Dose Imatinib.. <i>Blood</i> , 2009, 114, 2208-2208.	1.4	0
45	Cytochrome P450 2C9 *2 and *3 Polymorphisms and the Dose and Effect of Sulfonylurea in Type II Diabetes Mellitus. <i>Clinical Pharmacology and Therapeutics</i> , 2008, 83, 288-292.	4.7	113
46	Association of graded allele-specific changes in CYP2D6 function with imipramine dose requirement in a large group of depressed patients. <i>Molecular Psychiatry</i> , 2008, 13, 597-605.	7.9	42
47	Covariates of tramadol disposition in the first months of life. <i>British Journal of Anaesthesia</i> , 2008, 100, 525-532.	3.4	60
48	Subclinical hypocalcaemia in captive Asian elephants ( <i>Elephas maximus</i> ). <i>Veterinary Record</i> , 2008, 162, 475-479.	0.3	16
49	Vitamin K Epoxide Reductase Complex Subunit 1 (VKORC1) Polymorphism and Aortic Calcification. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2008, 28, 771-776.	2.4	35
50	Clinical Impact of New Prostate-Specific Antigen WHO Standardization on Biopsy Rates and Cancer Detection. <i>Clinical Chemistry</i> , 2008, 54, 1999-2006.	3.2	26
51	C-kit Asp-816-Val Mutation Analysis in Patients with Mastocytosis. <i>Dermatology</i> , 2007, 214, 15-20.	2.1	52
52	Hepatotoxicity of oral and intravenous voriconazole in relation to cytochrome P450 polymorphisms. <i>Journal of Antimicrobial Chemotherapy</i> , 2007, 60, 1104-1107.	3.0	78
53	Expression of activin and inhibin subunits, receptors and binding proteins in Human adrenocortical neoplasms. <i>Clinical Endocrinology</i> , 2006, 65, 792-799.	2.4	27
54	Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism. <i>British Journal of Clinical Pharmacology</i> , 2006, 61, 148-154.	2.4	200

#	ARTICLE	IF	CITATIONS
55	Circulating Free Insulin-Like Growth Factor (IGF)-I , Total IGF-I, and IGF Binding Protein-3 Levels Do Not Predict the Future Risk to Develop Prostate Cancer: Results of a Case-Control Study Involving 201 Patients within a Population-Based Screening with a 4-Year Interval. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2004, 89, 4391-4396.	3.6	42
56	Prediction of Irinotecan Pharmacokinetics by Use of Cytochrome P450 3A4 Phenotyping Probes. <i>Journal of the National Cancer Institute</i> , 2004, 96, 1585-1592.	6.3	113
57	The risk of bleeding complications in patients with cytochrome P450 CYP2C9*2 or CYP2C9*3 alleles on acenocoumarol or phenprocoumon. <i>Thrombosis and Haemostasis</i> , 2004, 92, 61-66.	3.4	89
58	Pharmacogenetics in Immunosuppressive Therapy. <i>Therapeutic Drug Monitoring</i> , 2004, 26, 343-346.	2.0	14
59	Variations in activin receptor, inhibin/activin subunit and follistatin mRNAs in human prostate tumour tissues. <i>British Journal of Cancer</i> , 2000, 82, 112-117.	6.4	33